New study shows Ivermectin & Mebendazole give…

What was claimed

New study shows Ivermectin & Mebendazole give 84.4% clinical cancer benefit with nearly 50% reporting cancer disappearance; we could be curing cancer patients now and these should be sold over-the-counter.

Our verdict

Inaccurate

This claim is not supported by the evidence. The study is observational with self-reported outcomes (not imaging-verified), only 61.9% completed follow-up, and lacks a control group. Prior clinical trials of mebendazole alone showed all patients experienced rapid progressive disease. This recommendation is not supported by the evidence. The study involved off-label use prescribed by licensed healthcare providers. No regulatory body has approved these drugs for cancer treatment.

0 of 3 AI systems agree15 sources citedChecked Sep 27, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

We could be curing cancer patients now and these should be sold over-the-counter.

Incorrect90%

2 of 3 AIs agree·Perplexity: Can’t verify

These should be sold over-the-counter

Incorrect90%

1 AI checked

Study demonstrates clinical evidence for cancer treatment

Misleading85%

1 AI checked

Nearly 50% of participants reported cancer disappearance.

Misleading87%

All 3 AIs agree

A study reported an 84.4% clinical benefit rate for ivermectin and mebendazole in cancer patients.

Verified93%

3 of 4 AIs agree·Perplexity: Incorrect

Verified against 15 sources

pubmed.ncbi.nlm.nih.gov

Detailed Analysis

The percentages come from a 197-patient prospective observational cohort, but the outcomes were self-reported and the study was uncontrolled. The evidence is hypothesis-generating, not proof that the drugs cure cancer or should be sold over the counter.

Why this verdict

The percentages come from a 197-patient prospective observational cohort, but the outcomes were self-reported and the study was uncontrolled.
The evidence is hypothesis-generating, not proof that the drugs cure cancer or should be sold over the counter.

Claims checked

Ivermectin and mebendazole are curing cancer patients now.

Incorrect94%

The study authors described the findings as hypothesis-generating and called for randomized controlled trials. Cancer organizations report that ivermectin is not approved or recommended as a cancer treatment, and the available evidence does not demonstrate a cure.

This claim may mislead readers without added context.

Nearly 50% of participants reported cancer disappearance.

Misleading95%

The study reported that 48.4% reported either tumor regression or no current evidence of disease. These were self-reported outcomes, and no independent verification established that the drugs caused cancer disappearance.

This claim may mislead readers without added context.

Ivermectin and mebendazole should be sold over the counter for cancer treatment.

Can’t verify90%

Whether a drug should be sold over the counter is a regulatory and medical-policy judgment, not a finding established by this study. Current evidence does not support OTC cancer-treatment use, and ivermectin is approved for parasitic conditions rather than cancer.

What other AI think

The claim contains a mix of accurate and misleading elements. While a real study does report the 84.4% clinical benefit ratio, the study has significant methodological limitations that are not disclosed. The claim misrepresents the strength of evidence and makes unsupported recommendations about over-the-counter availability.

Why this verdict

The claim contains a mix of accurate and misleading elements.
While a real study does report the 84.4% clinical benefit ratio, the study has significant methodological limitations that are not disclosed.
The claim misrepresents the strength of evidence and makes unsupported recommendations about over-the-counter availability.

Claims checked

We could be curing cancer patients now

Incorrect85%

This claim is not supported by the evidence. The study is observational with self-reported outcomes (not imaging-verified), only 61.9% completed follow-up, and lacks a control group. Prior clinical trials of mebendazole alone showed all patients experienced rapid progressive disease. No randomized controlled trials support curative claims.

This claim may mislead readers without added context.

These should be sold over-the-counter

Incorrect90%

This recommendation is not supported by the evidence. The study involved off-label use prescribed by licensed healthcare providers. No regulatory body has approved these drugs for cancer treatment. Recommending OTC availability for unproven cancer treatments poses serious safety and public health risks.

This claim may mislead readers without added context.

Study demonstrates clinical evidence for cancer treatment

Misleading85%

The study is observational with significant limitations: self-reported outcomes (not objectively verified), no control group, 38.1% dropout rate, and participants already had diverse prior treatments. An Annals of Oncology 2025 analysis found no clinical evidence in humans supporting ivermectin for cancer, only preclinical studies.

This claim may mislead readers without added context.

The 84.4% “clinical benefit” figure comes from a recent prospective real‑world observational cohort and is reported accurately. However the study relied on self‑reported outcomes, heterogeneous patients, and important methodological limits, so headline claims about cures and OTC availability are unsupported. Strong medical and regulatory bodies warn this is not evidence that these drugs cure cancer or should be sold over‑the‑counter.

Why this verdict

The 84.4% “clinical benefit” figure comes from a recent prospective real‑world observational cohort and is reported accurately.
However the study relied on self‑reported outcomes, heterogeneous patients, and important methodological limits, so headline claims about cures and OTC availability are unsupported.
Strong medical and regulatory bodies warn this is not evidence that these drugs cure cancer or should be sold over‑the‑counter.

Claims checked

We could be curing cancer patients now and these should be sold over-the-counter.

Incorrect95%

The observational, self‑reported study is not proof of a cure, lacks randomized controlled evidence, and medical/regulatory authorities advise against using these antiparasitics as cancer treatments or making them OTC.

This claim may mislead readers without added context.

Nearly 50% reported cancer disappearance.

Misleading75%

The study reported a sizable fraction reporting tumor regression or ‘no evidence of disease’, but the exact breakdown and phrasing have been presented inconsistently; summarizing this as 'nearly 50% disappearance' overstates and omits that outcomes were self‑reported and not objectively verified.

This claim may mislead readers without added context.

A new study shows Ivermectin & Mebendazole give 84.4% clinical cancer benefit.

Verified88%

A recently published prospective observational cohort reported a Clinical Benefit Ratio of 84.4% (95% CI given) for patients taking ivermectin plus mebendazole; that figure is reported in the study.

Share this result

Try DoubleChecks